Literature DB >> 22488099

The glasgow prognostic score as a predictor of survival in patients with potentially resectable pancreatic adenocarcinoma.

Marco La Torre1, Giuseppe Nigri, Marco Cavallini, Paolo Mercantini, Vincenzo Ziparo, Giovanni Ramacciato.   

Abstract

BACKGROUND: Survival rates after resection of pancreatic adenocarcinoma are poor; however, several tumor-related prognostic factors have been identified. There is increasing evidence that additional patient-related prognostic factors, such as ongoing systemic inflammatory response, are associated with poor outcomes in patients with common solid tumors. The purpose of this study was to evaluate the prognostic significance of the modified glasgow prognostic score (mGPS) in resected pancreatic ductal adenocarcinoma.
METHODS: Data were collected from 101 patients who had undergone pancreatic resection for ductal adenocarcinoma. Tumor and host factors were analyzed by Kaplan-Meier and Cox proportional hazard models to evaluate their potential prognostic effects.
RESULTS: An elevated mGPS was associated with lower overall survival rate after pancreatic resection. The median actuarial survival rate for patients with an mGPS of 0, 1, or 2 was 37.2, 11.5, and 7.3, respectively (p = 0.0001). The Cox proportional hazards model, including all the parameters statistically significant at univariate analysis, demonstrated that mGPS, lymph node ratio (LNR), and positive resection margins were independent negative prognostic factors
CONCLUSIONS: Margin involvement, LNR, and the preoperative mGPS were identified as independent predictors of survival in patients undergoing potentially curative pancreatic resection. Based on the present results and existing validation literature, the mGPS should be included in the routine assessment of patients with pancreatic cancer to better stratify patients for entry into therapeutic trials.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22488099     DOI: 10.1245/s10434-012-2348-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  50 in total

Review 1.  Borderline resectable pancreatic cancer.

Authors:  Bhargava Mullapudi; Patrick J Hawkes; Asish Patel; Chandrakanth Are; Subhasis Misra
Journal:  Indian J Surg Oncol       Date:  2015-01-04

2.  Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma.

Authors:  Matthieu Sarabi; Laetitia Mais; Nadia Oussaid; Françoise Desseigne; Pierre Guibert; Christelle De La Fouchardiere
Journal:  Oncol Lett       Date:  2017-04-20       Impact factor: 2.967

Review 3.  Prognostic significance of pre-operative C-reactive protein and the neutrophil-lymphocyte ratio in resectable pancreatic cancer: a systematic review.

Authors:  Lewis Stevens; Samir Pathak; Quentin M Nunes; Sanjay Pandanaboyana; Christian Macutkiewicz; Neil Smart; Andrew M Smith
Journal:  HPB (Oxford)       Date:  2014-11-27       Impact factor: 3.647

4.  Prognostic indicators based on inflammatory and nutritional factors after pancreaticoduodenectomy for pancreatic cancer.

Authors:  Joji Watanabe; Shinji Otani; Teruhisa Sakamoto; Yosuke Arai; Takehiko Hanaki; Masataka Amisaki; Naruo Tokuyasu; Soichiro Honjo; Masahide Ikeguchi
Journal:  Surg Today       Date:  2016-02-11       Impact factor: 2.549

5.  Prognostic significance of the modified Glasgow prognostic score in elderly patients with gastric cancer.

Authors:  Kotaro Hirashima; Masayuki Watanabe; Hironobu Shigaki; Yu Imamura; Satoshi Ida; Masaaki Iwatsuki; Takatsugu Ishimoto; Shiro Iwagami; Yoshifumi Baba; Hideo Baba
Journal:  J Gastroenterol       Date:  2013-07-03       Impact factor: 7.527

6.  Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores.

Authors:  Inhwan Hwang; Jihoon Kang; Hei Nga Natalie Ip; Jae Ho Jeong; Kyu-Pyo Kim; Heung-Moon Chang; Changhoon Yoo; Baek-Yeol Ryoo
Journal:  Invest New Drugs       Date:  2018-10-16       Impact factor: 3.850

7.  The C-reactive Protein to Albumin Ratio Predicts Long-Term Outcomes in Patients with Pancreatic Cancer After Pancreatic Resection.

Authors:  Koichiro Haruki; Hiroaki Shiba; Yoshihiro Shirai; Takashi Horiuchi; Ryota Iwase; Yuki Fujiwara; Kenei Furukawa; Takeyuki Misawa; Katsuhiko Yanaga
Journal:  World J Surg       Date:  2016-09       Impact factor: 3.352

8.  Pancreatic cancer and predictors of survival: comparing the CA 19-9/bilirubin ratio with the McGill Brisbane Symptom Score.

Authors:  Sinziana Dumitra; Mohammad H Jamal; Jad Aboukhalil; Suhail A Doi; Prosanto Chaudhury; Mazen Hassanain; Peter P Metrakos; Jeffrey S Barkun
Journal:  HPB (Oxford)       Date:  2013-03-22       Impact factor: 3.647

9.  A Preoperative Prognostic Scoring System to Predict Prognosis for Resectable Pancreatic Cancer: Who Will Benefit from Upfront Surgery?

Authors:  Toru Nakamura; Toshimichi Asano; Keisuke Okamura; Takahiro Tsuchikawa; Soichi Murakami; Yo Kurashima; Yuma Ebihara; Takehiro Noji; Yoshitsugu Nakanishi; Kimitaka Tanaka; Toshiaki Shichinohe; Satoshi Hirano
Journal:  J Gastrointest Surg       Date:  2018-09-21       Impact factor: 3.452

10.  New prognostic score for the survival of patients with esophageal squamous cell carcinoma.

Authors:  Masaki Nakamura; Makoto Iwahashi; Mikihito Nakamori; Toshiyasu Ojima; Masahiro Katsuda; Takeshi Iida; Keiji Hayata; Tomoya Kato; Hiroki Yamaue
Journal:  Surg Today       Date:  2013-06-20       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.